undefined
The trademark CARUXIN was filed by MACURE PHARMA ApS, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on January 29, 2023, and received one opposition filed on May 1, 2023 by Novartis AG on Likelihood of confusion. the opponent was represented by Nordemann Czychowski & Partner Rechtsanwältinnen und Rechtsanwälte mbB and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued May 1, 2023
The application was filed in Danish, and Danish was also language of all opposition proceedings (English was selected as the second language).